543
Participants
Start Date
December 31, 2004
Study Completion Date
December 31, 2005
Xarelto (Rivaroxaban, BAY59-7939)
BAY59-7939 20 mg once daily (od) for 12 weeks
Xarelto (Rivaroxaban, BAY59-7939)
BAY59-7939 30 mg od for 12 weeks
Xarelto (Rivaroxaban, BAY59-7939)
BAY59-7939 40 mg od for 12 weeks
(LMW) Heparin + Vitamin K Antagonist
Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
Frederiksberg
Sydney
Johannesburg
Johannesburg
Johannesburg
Johannesburg
Sydney
Canberra
Melbourne
Melbourne
Melbourne
Brisbane
Aarhus
Brædstrup
Prague
Safed
Afula
Milan
Milan
Milan
Fredericksburg
Pavia
Brest
Venezia
Haifa
Haifa
Montpellier
Haifa
Padua
Grenoble
Saint-Etienne
Reggio Emilia
Kfar Saba
Petah Tikva
Tel Litwinsky
Holon
Valenciennes
Tel Aviv
Paris
Paris
Ashkelon
Albuquerque
Seattle
Albuquerque
Chapel Hill
Curitiba
Porto Alegre
São Paulo
Sorocaba
Edmonton
Halifax
London
Hradec Králové
Karlovy Vary
Ostrava
Pilsen
Prague
Ústí nad Labem
Amersfoort
Amsterdam
Amsterdam
Arnhem
Groningen
Hoofddorp
Maastricht
Sittard-geleen
Zwolle
Warsaw
Bydgoszcz
Warsaw
Wroclaw
Wroclaw
Johannesburg
Gothenburg
Jönköping
Stockholm
Stockholm
Västervik
Lead Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
Bayer
INDUSTRY